| Ticker Details |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
|
| IPO Date: |
September 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.22B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 3.08%
|
| Avg Daily Range (30 D): |
$0.37 | 2.34%
|
| Avg Daily Range (90 D): |
$0.35 | 2.16%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.7M |
| Avg Daily Volume (30 D): |
.98M |
| Avg Daily Volume (90 D): |
1.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
161 |
| Avg Trade Size (Sh.) (30 D): |
67 |
| Avg Trade Size (Sh.) (90 D): |
74 |
| Institutional Trades |
| Total Institutional Trades: |
2,781 |
| Avg Institutional Trade: |
$1.36M |
| Avg Institutional Trade (30 D): |
$1.93M |
| Avg Institutional Trade (90 D): |
$2.42M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.46M |
| Avg Closing Trade (30 D): |
$2.07M |
| Avg Closing Trade (90 D): |
$2.57M |
| Avg Closing Volume: |
131.81K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$2.39
|
$.29
|
$.26
|
|
Diluted EPS
|
$2.29
|
$.28
|
$.25
|
|
Revenue
|
$311.51M
|
$83.22M
|
$77.71M
|
|
Gross Profit
|
$281.47M
|
$76.67M
|
$71.2M
|
|
Net Income / Loss
|
$314.11M
|
$37.41M
|
$34.36M
|
|
Operating Income / Loss
|
$150.75M
|
$46.34M
|
$41.42M
|
|
Cost of Revenue
|
$30.04M
|
$6.56M
|
$6.51M
|
|
Net Cash Flow
|
$126.83M
|
$138.82M
|
$-39.21M
|
|
PE Ratio
|
|
|
|
|
|
|
